Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.74 |
| ▸ | SELL | P14151 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.51 |
| ▸ | MAG | P20916 | 3/20 | 0.48 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CD22 | P20273 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066109 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL28161285 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL15976325 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL13125452 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL2742889 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL8664558 | 0.92 | NANP (0.64) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL9253179 | 0.92 | NANP (0.63) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL14601223 | 0.91 | NANP (0.63) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL23366254 | 0.91 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL7263212 | 0.91 | NANP (0.62) | NANPSELLSELPMAGSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325936-B2 | Sialidase inhibitors and preparation thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200190130-A1 | SIALIDASE INHIBITORS AND PREPARATION THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-18 | — | — | US | disclosed |
| US-9382284-B2 | Neuraminidase inhibitor compounds, compositions and methods for the use thereof in anti-viral treatments | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-05 | — | — | US | disclosed |
| US-20150216838-A1 | Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof in Anti-Viral Treatments | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-08-06 | — | — | US | disclosed |
| EP-2454268-B1 | 2,3-FLUORINATED GLYCOSIDES AS NEURAMINIDASE INHIBITORS AND THEIR USE AS ANTI-VIRALS | UNIV BRITISH COLUMBIA (CA) | 2014-09-10 | — | — | EP | disclosed |
| EP-0957107-B1 | NOVEL COMPOUNDS HAVING ANTIVIRAL ACTIVITY | NISSIN FOOD PRODUCTS LTD (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325936-B2 | Sialidase inhibitors and preparation thereof | NEU2, NEU1, NEU3 | NANP 31/4885SELL 1097/4885SELP 668/4885 |
| US-20150216838-A1 | Neuraminidase Inhibitor Compounds, Compositions and Methods for the Use Thereof in Anti-Viral Treatments | NEU1, NEU3, NEU2 | NANP 69/4885SELL 1729/4885SELP 666/4885 |
| US-20200190130-A1 | SIALIDASE INHIBITORS AND PREPARATION THEREOF | NEU2, NEU1, NEU3 | NANP 31/4885SELL 1097/4885SELP 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.